Naveen Pemmaraju: Wonderful discussion and exchange of ideas with Ruben Mesa and John Mascarhenas at ASCO24

Naveen Pemmaraju shared a post on LinkedIn:

“A truly wonderful discussion and exchange of ideas on the state of the MPN field last night at ASCO24 with PVI, Peer View Institute for Medical Education Myelofibrosis Symposium as I was joined by my distinguished colleagues Ruben Mesa and John Mascarhenas.

We reviewed together current clinical data for standard of care treatment options including alloSCT, JAKi, as well as some clinical trials/newer combination approaches, and sequencing of JAKi in clinical practice.”

Source: Naveen Pemmaraju/LinkedIn

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.